Facility ExpansionThe expansion of the Canadian facility, with an 83% increase in quarterly orders and a 93% increase in orders from new clients, supports future growth despite the Dutch divestiture.
Financial PerformanceImmunoPrecise Antibodies (IPA) reported positive financial results for their 4Q25, including revenues of CDN$7.0 million, up 8% year-over-year, with a reduced net loss of $2.2 million.
R&D AchievementsIPA has been very busy on the R&D front, highlighted by several recent breakthroughs achieved by the Company’s LENSai platform.